These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32318637)

  • 21. Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women.
    Kok P; Roelfsema F; Frölich M; van Pelt J; Stokkel MP; Meinders AE; Pijl H
    Am J Physiol Endocrinol Metab; 2006 Nov; 291(5):E1038-43. PubMed ID: 16803851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of dopamine D2 receptors lowers circadian leptin concentrations in obese women.
    Kok P; Roelfsema F; Frölich M; van Pelt J; Meinders AE; Pijl H
    J Clin Endocrinol Metab; 2006 Aug; 91(8):3236-40. PubMed ID: 16705078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased lean body mass as an early indicator of olanzapine-induced weight gain in healthy men.
    Daurignac E; Leonard KE; Dubovsky SL
    Int Clin Psychopharmacol; 2015 Jan; 30(1):23-8. PubMed ID: 25350366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study.
    Smith RC; Maayan L; Wu R; Youssef M; Jing Z; Sershen H; Szabo V; Meyers J; Jin H; Zhao J; Davis JM
    Psychopharmacology (Berl); 2018 Dec; 235(12):3545-3558. PubMed ID: 30382354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers.
    Toledo FGS; Martin WF; Morrow L; Beysen C; Bajorunas D; Jiang Y; Silverman BL; McDonnell D; Namchuk MN; Newcomer JW; Graham C
    Neuropsychopharmacology; 2022 Feb; 47(3):696-703. PubMed ID: 34887529
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic and body mass parameters after treatment with JNJ-37822681, a novel fast-dissociating D2 receptor antagonist, vs olanzapine in patients with schizophrenia.
    Daly EJ; Kent JM; Janssens L; Newcomer JW; Hüsken G; De Boer P; Tritsmans L; Schmidt ME
    Ann Clin Psychiatry; 2013 Aug; 25(3):173-83. PubMed ID: 23926573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.
    Markham A; Benfield P
    CNS Drugs; 1997 Apr; 7(4):328-40. PubMed ID: 27520755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin secretion and sensitivity after single-dose amisulpride, olanzapine or placebo in young male subjects: double blind, cross-over glucose clamp study.
    Kopf D; Gilles M; Paslakis G; Medlin F; Lederbogen F; Lehnert H; Deuschle M
    Pharmacopsychiatry; 2012 Sep; 45(6):223-8. PubMed ID: 22426845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.
    Meyer JM
    J Clin Psychiatry; 2002 May; 63(5):425-33. PubMed ID: 12019668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic disturbances independent of body mass in patients with schizophrenia taking atypical antipsychotics.
    Kang SH; Lee JI
    Psychiatry Investig; 2015 Apr; 12(2):242-8. PubMed ID: 25866526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glibenclamide improves postprandial hypertriglyceridaemia in type 2 diabetic patients by reducing chylomicrons but not the very low-density lipoprotein subfraction levels.
    Skrapari I; Perrea D; Ioannidis I; Karabina SA; Elisaf M; Tselepis AD; Karagiannacos P; Katsilambros N
    Diabet Med; 2001 Oct; 18(10):781-5. PubMed ID: 11678967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study.
    Matikainen N; Söderlund S; Björnson E; Pietiläinen K; Hakkarainen A; Lundbom N; Taskinen MR; Borén J
    Diabetes Obes Metab; 2019 Jan; 21(1):84-94. PubMed ID: 30073766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of the adverse effects of olanzapine on lipid metabolism with the antiepileptic zonisamide.
    Stefanidis A; Watt MJ; Cowley MA; Oldfield BJ
    Neuropharmacology; 2017 Sep; 123():55-66. PubMed ID: 28400260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A crossover study on lipid and weight changes associated with olanzapine and risperidone.
    Su KP; Wu PL; Pariante CM
    Psychopharmacology (Berl); 2005 Dec; 183(3):383-6. PubMed ID: 16240162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis.
    Kadakia A; Dembek C; Heller V; Singh R; Uyei J; Hagi K; Nosaka T; Loebel A
    BMC Psychiatry; 2021 May; 21(1):249. PubMed ID: 33975574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.
    Smith RC; Lindenmayer JP; Davis JM; Kelly E; Viviano TF; Cornwell J; Hu Q; Khan A; Vaidhyanathaswamy S
    J Clin Psychiatry; 2009 Nov; 70(11):1501-13. PubMed ID: 19814947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
    J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial.
    Baptista T; Rangel N; Fernández V; Carrizo E; El Fakih Y; Uzcátegui E; Galeazzi T; Gutiérrez MA; Servigna M; Dávila A; Uzcátegui M; Serrano A; Connell L; Beaulieu S; de Baptista EA
    Schizophr Res; 2007 Jul; 93(1-3):99-108. PubMed ID: 17490862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of novel antipsychotics on glucose and lipid levels.
    Wirshing DA; Boyd JA; Meng LR; Ballon JS; Marder SR; Wirshing WC
    J Clin Psychiatry; 2002 Oct; 63(10):856-65. PubMed ID: 12416594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipid-lowering effects of tetradecylthioacetic acid in antipsychotic-exposed, female rats: challenges with long-term treatment.
    Skrede S; Fernø J; Bjørndal B; Brede WR; Bohov P; Berge RK; Steen VM
    PLoS One; 2012; 7(11):e50853. PubMed ID: 23226405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.